Starpharma Beta
Quel est le Beta de Starpharma?
Le Beta de Starpharma Holdings Limited est 1.12
Quelle est la définition de Beta?
BETA indique si une action est plus ou moins volatile que le marché dans son ensemble. Un bêta inférieur à 1 indique que l'action est moins volatile que le marché, tandis qu'un bêta supérieur à 1 indique que l'action est plus volatile. La volatilité est mesurée par la fluctuation du prix autour de la moyenne.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta des entreprises dans Health Care secteur sur ASX par rapport à Starpharma
Que fait Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Entreprises avec beta similaire à Starpharma
- Broadcom a Beta de 1.12
- WestRock a Beta de 1.12
- Navient Corp a Beta de 1.12
- U.S. Well Services a Beta de 1.12
- Zephyr plc a Beta de 1.12
- United Parcel Service a Beta de 1.12
- Starpharma a Beta de 1.12
- Howmet Aerospace Inc a Beta de 1.12
- Excellon Resources a Beta de 1.12
- Gyscoal Alloys a Beta de 1.12
- RattanIndia Infrastructure a Beta de 1.12
- RattanIndia Infrastructure a Beta de 1.12
- Lion a Beta de 1.12